{"title":"Resveratrol in ulcerative colitis: therapeutic mechanisms, animal model evidence and novel approaches.","authors":"Yukta Garg, Nandini Sharma, Shivang Saxena, Nihar Ranjan Sahoo, Sushil Kumar, Sankushdeep Singh, Amandeep Singh","doi":"10.1080/1061186X.2025.2469750","DOIUrl":null,"url":null,"abstract":"<p><p>Ulcerative colitis is a type of chronic inflammatory bowel disease characterised by abdominal pain, bloody diarrhoea, rectal bleeding and ulcerations in colon. This illness has significant health risks as it easily relapses, thus, providing a considerable threat to human health. A number of inflammatory mediators, oxidative stress and role of gut microbes have been studied thoroughly to understand the exact pathophysiology behind the disease occurrence. Several conventional therapies are available for the treatment of ulcerative colitis but each one of them have one or the other side effect. Therefore, to overcome this limitation, we are moving ahead towards herbal drug therapies. The current review presents the emerging role of Resveratrol, a natural occurring polyphenol derived from plant species. It is associated with potential antioxidative and anti-inflammatory properties. Protective effects of Resveratrol in different ulcerative colitis induced animal models are discussed in this review. Various strategies to improve bioavailability of drug include encapsulation of drug in several nanocarriers. Although many animal models have proved the effectiveness of Resveratrol in the treatment of ulcerative colitis, further research on human subjects is still required to understand the exact mechanism and safety to establish its uses clinically.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-24"},"PeriodicalIF":4.3000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Targeting","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1061186X.2025.2469750","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Ulcerative colitis is a type of chronic inflammatory bowel disease characterised by abdominal pain, bloody diarrhoea, rectal bleeding and ulcerations in colon. This illness has significant health risks as it easily relapses, thus, providing a considerable threat to human health. A number of inflammatory mediators, oxidative stress and role of gut microbes have been studied thoroughly to understand the exact pathophysiology behind the disease occurrence. Several conventional therapies are available for the treatment of ulcerative colitis but each one of them have one or the other side effect. Therefore, to overcome this limitation, we are moving ahead towards herbal drug therapies. The current review presents the emerging role of Resveratrol, a natural occurring polyphenol derived from plant species. It is associated with potential antioxidative and anti-inflammatory properties. Protective effects of Resveratrol in different ulcerative colitis induced animal models are discussed in this review. Various strategies to improve bioavailability of drug include encapsulation of drug in several nanocarriers. Although many animal models have proved the effectiveness of Resveratrol in the treatment of ulcerative colitis, further research on human subjects is still required to understand the exact mechanism and safety to establish its uses clinically.
期刊介绍:
Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs.
Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns.